Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

18F CTT 1057

Next Previous
X
Search
Drug Profile

18F CTT 1057

Alternative Names: [18F]CTT1057; CTT-1057; CTT-1057-18F; CTT-1057-F-18; Fluorine-18-CTT 1057

Latest Information Update: 21 Feb 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Targeted Technology
  • Developer Cancer Targeted Technology; Novartis Pharmaceuticals
  • Class Imaging agents; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Positron-emission tomography enhancers; Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Prostate cancer
  • No development reported Renal cell carcinoma

Most Recent Events

  • 21 Feb 2024 Novartis Pharmaceuticals completes phase-III clinical trials in Prostate cancer (Diagnosis) in Spain, France and Switzerland, US (IV) (EudraCT2020-003959-16) (NCT04838613)
  • 24 Nov 2023 Novartis completes a phase II/III clinical trials in Prostate cancer (Diagnosis) in Switzerland, Spain, Italy, USA and France (IV) (NCT04838626)
  • 30 Sep 2021 Phase-III clinical trials in Prostate cancer (Diagnosis) in USA, Switzerland (IV) (EudraCT2020-003959-16) (NCT04838613)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top